Publication at First Faculty of Medicine |
2013
Abstract
Denosumab (anti-receptor aktivátor of nuclear factor kB ligand antibody) is a fully human monoclonal antibody (IgG2) that inhibits osteoclastic-mediated bone resorption by binding to ligand (RANKL) and preventing activation of the receptor RANK on osteoklast and their precursors. Denosumab has a rapid onset and offset effect.
Denosumab (60mg subcutaneously every 6 months) significantly reduced vertebral, nonvertebral and hip fracture risk compared with placebo and had an excellent safety profile